الإحصائيات الأساسية
| CIK | 1360214 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Harrow, Inc.
SEC Filings (Chronological Order)
توفر هذه الصفحة قائمة كاملة ومرتبة ترتيبًا زمنيًا لتصريحات هيئة الأوراق المالية والبورصات، باستثناء تصريحات الملكية التي نقدمها في مكان آخر.
| August 25, 2025 |
AMENDED AND RESTATED BYLAWS HARROW, INC. a Delaware corporation ARTICLE 1 Exhibit 3.1 AMENDED AND RESTATED BYLAWS OF HARROW, INC. a Delaware corporation ARTICLE 1 OFFICES Section 1.1 Registered Office. The registered office of the Corporation in the State of Delaware shall be set forth in the Certificate of Incorporation of the Corporation. Section 1.2 Other Offices. The Corporation may also have offices at such other places, either within or without the State of Delawa |
|
| August 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 21, 2025 HARROW, INC. (Exact name of registrant as specified in its charter) Delaware 001-35814 45-0567010 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| August 11, 2025 |
Harrow Corporate Presentation dated August 2025 Exhibit 99.3 |
|
| August 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35814 Harrow, Inc. (Exact n |
|
| August 11, 2025 |
Form of Incentive Stock Option Agreement Exhibit 10.2 HARROW, INC. 2025 INCENTIVE STOCK AND AWARDS PLAN INCENTIVE STOCK OPTION AGREEMENT This INCENTIVE STOCK OPTION AGREEMENT (the “Option Agreement”), dated [](the “Grant Date”), is between Harrow, Inc., a Delaware corporation (the “Company”), and [] (the “Optionee”), an employee of the Company, pursuant to the Harrow, Inc. 2025 Incentive Stock and Awards Plan (the “Plan”). WHEREAS, the C |
|
| August 11, 2025 |
Harrow Announces Second-Quarter 2025 Financial Results Exhibit 99.1 Harrow Announces Second-Quarter 2025 Financial Results Second-Quarter 2025 and Recent Selected Highlights: ● Total revenues of $63.7 million, a 30% increase over $48.9 million recorded in the prior-year period ● GAAP net income of $5.0 million ● Adjusted EBITDA of $17.0 million ● Cash and cash equivalents of $53.0 million as of June 30, 2025 NASHVILLE, Tenn., August 11, 2025 – Harrow |
|
| August 11, 2025 |
Form of Non-Qualified Stock Option Agreement Exhibit 10.3 HARROW, INC. 2025 INCENTIVE STOCK AND AWARDS PLAN FORM OF NONQUALIFIED STOCK OPTION AGREEMENT This NONQUALIFIED STOCK OPTION AGREEMENT (the “Option Agreement”), dated as of [] (the “Grant Date”), is between Harrow, Inc., a Delaware corporation (the “Company”), and [] (the “Optionee”), an employee or consultant of the Company or of a Subsidiary of the Company (a “Related Corporation”), |
|
| August 11, 2025 |
Letter to Stockholders August 11, 2025 Exhibit 99.2 Letter to Stockholders August 11, 2025 Dear Harrow Stockholders: As we report on the second quarter of 2025, Harrow continues to solidify its position as a leading provider of ophthalmic disease management solutions in North America. Our comprehensive portfolio of trusted ophthalmic products addresses a broad range of eye conditions in both the front and back of the eye – including dr |
|
| August 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2025 HARROW, INC. (Exact name of registrant as specified in its charter) Delaware 001-35814 45-0567010 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| August 11, 2025 |
Form of Restricted Stock Unit Agreement Exhibit 10.4 HARROW, INC. 2025 INCENTIVE STOCK AND AWARDS PLAN NOTICE OF Restricted Stock Unit AWARD Grantee’s Name and Address: You (the “Grantee”) have been granted an award of Restricted Stock Units (the “Award”), subject to the terms and conditions of this Notice of Restricted Stock Unit Award (the “Notice”), the Harrow, Inc. 2025 Incentive Stock and Awards Plan, as amended from time to time ( |
|
| July 17, 2025 |
Exhibit 99 Harrow Enters into Commercialization Agreement with Samsung Bioepis for Ophthalmology Biosimilars Portfolio in the United States Harrow to assume full commercial responsibility for BYOOVIZ® and OPUVIZ™ by the end of 2025 NASHVILLE, Tenn. |
|
| July 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 17, 2025 HARROW, INC. (Exact name of registrant as specified in its charter) Delaware 001-35814 45-0567010 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| June 20, 2025 |
As filed with the Securities and Exchange Commission on June 20, 2025 As filed with the Securities and Exchange Commission on June 20, 2025 Registration No. |
|
| June 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 18, 2025 HARROW, INC. (Exact name of registrant as specified in its charter) Delaware 001-35814 45-0567010 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| June 20, 2025 |
Exhibit 107 Calculation of Filing Fee Tables Form S-8 (Form Type) HARROW, INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Fees Previously Paid Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Share(2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee(3) Equity Common |
|
| June 9, 2025 |
Exhibit 99 Harrow Acquires U.S. Commercial Rights to BYQLOVI™ (Clobetasol Propionate Ophthalmic Suspension) 0.05% from Formosa Pharmaceuticals NASHVILLE, Tenn. and Taipei, Taiwan, June 9, 2025 – Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, and Taiwan-based Formosa Pharmaceuticals (“Formosa”, 6838.TW), today announced a licensing agreement, whereby Harrow has acqu |
|
| June 9, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2025 HARROW, INC. (Exact name of registrant as specified in its charter) Delaware 001-35814 45-0567010 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| May 8, 2025 |
Letter to Stockholders May 8, 2025 Exhibit 99.2 Letter to Stockholders May 8, 2025 Dear Harrow Stockholders: Today, we reported first-quarter 2025 revenues of $47.8 million, a 38% increase over the prior-year’s first-quarter revenues of $34.6 million and, as expected, a sequential decrease from fourth-quarter 2024 revenues. In addition to record-high cash flow from operations of $19.7 million for the quarter, a very bright spot was |
|
| May 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35814 Harrow, Inc. (Exact |
|
| May 8, 2025 |
Harrow Announces First-Quarter 2025 Financial Results Exhibit 99.1 Harrow Announces First-Quarter 2025 Financial Results First-Quarter 2025 and Recent Selected Highlights: ● Revenues of $47.8 million, a 38% increase over $34.6 million recorded in prior-year period ● VEVYE revenues increased to $21.5 million, a 35% increase from $16.0 million in the fourth quarter 2024 ● Cash flow from operations reached a record high of $19.7 million ● GAAP net loss |
|
| May 8, 2025 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2025 HARROW, INC. (Exact name of registrant as specified in its charter) Delaware 001-35814 45-0567010 (State or other jurisdiction of incorporation) (Commission File Number) ( |
|
| April 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive |
|
| April 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive |
|
| March 27, 2025 |
EXHIBIT 10.45 1A Burton Hills Blvd Nashville TN 37215 Main: 858.704.4040 Fax: 858.345.1745 www.harrowinc.com November 18, 2024 Dear Amir: We are pleased to extend the offer of employment (the “Offer Letter”) to you to serve as the Chief Scientific Officer at Harrow, Inc. (hereinafter, “Harrow”), reporting to Mark L. Baum, Chairman and Chief Executive Officer. Your target start date will be January |
|
| March 27, 2025 |
Letter to Stockholders March 27, 2025 Exhibit 99.2 Letter to Stockholders March 27, 2025 Dear Harrow Stockholders: We had a tremendous close to a monumental year – and today, I am pleased to report another period of record financial performance by the Harrow team, with fourth-quarter revenue of $66.8 million, an impressive 84% year-over-year increase. Revenues for 2024 increased 53% to $199.6 million, exceeding the 47% annual growth a |
|
| March 27, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2025 HARROW, INC. (Exact name of registrant as specified in its charter) Delaware 001-35814 45-0567010 (State or other jurisdiction of incorporation) (Commission File Number |
|
| March 27, 2025 |
Exhibit 21.1 HARROW, INC. SUBSIDIARIES as of December 31, 2024 Name of Subsidiary State of Incorporation or Organization ImprimisRx, LLC Delaware Imprimis NJOF, LLC New Jersey ImprimisRx NJ, LLC New Jersey Harrow Eye, LLC Delaware Harrow IP, LLC Delaware ImprimisRx Nashville, LLC Delaware Harrow Analytical Services, LLC Delaware |
|
| March 27, 2025 |
Harrow, Inc. Insider Trading Policy EXHIBIT 19 INSIDER TRADING 1. Purpose. This Insider Trading Policy (the “Policy”) provides guidelines with respect to transactions in the securities of Harrow, Inc. (the “Company”) and the handling of confidential information about the Company (including its subsidiaries) and the companies with which the Company does business. The Company’s Board of Directors has adopted this Policy to promote com |
|
| March 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35814 HARROW, INC. ( |
|
| March 27, 2025 |
Harrow Announces Fourth-Quarter and Year-End 2024 Audited Financial Results Exhibit 99.1 Harrow Announces Fourth-Quarter and Year-End 2024 Audited Financial Results Fourth-Quarter, Full-Year 2024, and Recent Highlights: ● Record revenues of $66.8 million for Q4 2024, an 84% increase over Q4 2023 ● Revenues of $199.6 million for FY 2024, a 53% increase over FY 2023 ● GAAP net income of $6.8 million for Q4 2024, for a GAAP net loss of $(17.5) million for FY 2024 ● Adjusted |
|
| March 17, 2025 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 17, 2025 HARROW, INC. (Exact name of registrant as specified in its charter) Delaware 001-35814 45-0567010 (State or other jurisdiction of incorporation) (Commission File Number |
|
| March 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC File Number: 001-35814 CUSIP Number: 415858109 NOTIFICATION OF LATE FILING (Check One) ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: December 31, 2024 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Tr |
|
| March 17, 2025 |
Exhibit 99.1 Harrow Provides Fourth Quarter and Year-End 2024 Unaudited Preliminary Financial Results and 2025 Revenue Guidance Company Expects to Provide Revised Dates for Release of Audited Financial Results, Conference Call, and Letter to Stockholders NASHVILLE, Tenn., March 17, 2025 – Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced unaudited prel |
|
| January 21, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 17, 2025 HARROW, INC. (Exact name of registrant as specified in its charter) Delaware 001-35814 45-0567010 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| December 5, 2024 |
HROW / Harrow, Inc. / Kaufman Daniel Louis - AMENDMENT NO. 2 TO SC13G Passive Investment SC 13G/A 1 sc13ga.htm AMENDMENT NO. 2 TO SC13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2) Harrow, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 415858109 (CUSIP Number) August 12, 2024 (Date of Event Which Requires Filing of this Statement) Check t |
|
| November 14, 2024 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2024 HARROW, INC. (Exact name of registrant as specified in its charter) Delaware 001-35814 45-0567010 (State or other jurisdiction of incorporation) (Commission File Num |
|
| November 14, 2024 |
EXHIBIT 10.1 SECOND AMENDMENT TO CREDIT AGREEMENT AND GUARANTY This SECOND AMENDMENT TO CREDIT AGREEMENT AND GUARANTY (this “Amendment”), dated as of October 25, 2024 (the “Second Amendment Effective Date”), is entered into by and among HARROW, INC. (formerly known as Harrow Health, Inc.), a Delaware corporation (the “Borrower”), the Guarantors (as defined in the Credit Agreement referred to below |
|
| November 14, 2024 |
Harrow Announces Third Quarter 2024 Financial Results Exhibit 99.1 Harrow Announces Third Quarter 2024 Financial Results Third Quarter 2024 and Recent Selected Highlights: ● Revenues increased 44% from $34.3 million in the prior-year quarter to $49.3 million ● GAAP net loss of $(4.2) million ● Adjusted EBITDA of $8.8 million ● Operating cash flow of $3 million ● Cash and cash equivalents of $72.6 million as of September 30, 2024 ● VEVYE® total prescr |
|
| November 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35814 Harrow, Inc. (Ex |
|
| November 14, 2024 |
Letter to Stockholders November 13, 2024 Exhibit 99.2 Letter to Stockholders November 13, 2024 Dear Harrow Stockholders: I began writing this Stockholder Letter from Madison, Wisconsin, at the home of an old friend who happens to be a Harrow founding stockholder. I asked him how he would describe our progress over the years, and he said, “Lots of bumps, twists, and turns along the way, especially the first ten years, but Harrow is becomi |
|
| October 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 25, 2024 HARROW, INC. (Exact name of registrant as specified in its charter) Delaware 001-35814 45-0567010 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| September 9, 2024 |
Harrow, Inc. Corporate Presentation September 2024 Exhibit 99.1 |
|
| September 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 9, 2024 HARROW, INC. (Exact name of registrant as specified in its charter) Delaware 001-35814 45-0567010 (State or other jurisdiction of incorporation) (Commission File Num |
|
| August 7, 2024 |
Harrow Announces Second Quarter 2024 Financial Results EXHIBIT 99.1 Harrow Announces Second Quarter 2024 Financial Results Second Quarter 2024 and Recent Selected Highlights: ● Record revenues of $48.9 million ● GAAP net loss of $(6.5) million ● Adjusted EBITDA of $8.8 million ● Cash and cash equivalents of $71.0 million as of June 30, 2024 ● IHEEZO® customer unit demand volume increased by 98% from the first quarter of 2024 ● IHEEZO supply agreements |
|
| August 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35814 Harrow, Inc. (Exact n |
|
| August 7, 2024 |
Letter to Stockholders August 7, 2024 EXHIBIT 99.2 Letter to Stockholders August 7, 2024 Dear Harrow Stockholders: My last Letter to Stockholders outlined three of Harrow’s key operational initiatives from our Five-Year Strategic Plan (see page 2 of my March 23, 2023 Letter to Stockholders): (1) building a formidable dry eye disease franchise, including successfully launching VEVYE®; (2) continuing to lay the foundation for Harrow’s r |
|
| August 7, 2024 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2024 HARROW, INC. (Exact name of registrant as specified in its charter) Delaware 001-35814 45-0567010 (State or other jurisdiction of incorporation) (Commission File Number |
|
| June 26, 2024 |
Letter from KMJ Corbin & Company LLP Exhibit 16 June 26, 2024 Office of the Chief Accountant Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Ladies and Gentlemen: We have read the comments made regarding us in Item 4.01 of Form 8-K of Harrow, Inc. dated June 24, 2024, and are in agreement with those statements. /s/ KMJ Corbin & Company LLP Irvine, California |
|
| June 26, 2024 |
Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 24, 2024 HARROW, INC. (Exact name of registrant as specified in its charter) Delaware 001-35814 45-0567010 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| June 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2024 HARROW, INC. (Exact name of registrant as specified in its charter) Delaware 001-35814 45-0567010 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| May 13, 2024 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2024 HARROW, INC. (Exact name of registrant as specified in its charter) Delaware 001-35814 45-0567010 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| May 13, 2024 |
Harrow Announces First Quarter 2024 Financial Results Exhibit 99.1 Harrow Announces First Quarter 2024 Financial Results First Quarter 2024 and Recent Selected Highlights: ● Revenues of $34.6 million, a 33% increase over the $26.1 million realized in the prior-year quarter. ● Received confirmation from the Centers for Medicare & Medicaid Services (CMS) on March 20 that IHEEZO is separately reimbursable for unilateral and bilateral in-office procedure |
|
| May 13, 2024 |
Letter to Stockholders May 13, 2024 Exhibit 99.2 Letter to Stockholders May 13, 2024 Dear Harrow Stockholders: Today marks the beginning of the 20th week of 2024 and the 134th day into the second year of Harrow’s current Five-Year Strategic Plan. This year remains focused on three key operational initiatives: (1) building a formidable dry eye disease franchise, including successfully launching VEVYE®; (2) continuing to lay the found |
|
| May 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35814 Harrow, Inc. (Exact |
|
| April 30, 2024 |
ETON / Eton Pharmaceuticals, Inc. / Imprimis Pharmaceuticals, Inc. Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Eton Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 29772L 108 (CUSIP Number) Harrow, Inc. 102 Woodmont Blvd., Suite 610 Nashville, Tennessee 37215 Attention: Andrew R. Boll (615) 733-4731 (Name, Ad |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive |
|
| March 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 20, 2024 HARROW, INC. (Exact name of registrant as specified in its charter) Delaware 001-35814 45-0567010 (State or other jurisdiction of incorporation) (Commission File Number |
|
| March 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 19, 2024 HARROW, INC. (Exact name of registrant as specified in its charter) Delaware 001-35814 45-0567010 (State or other jurisdiction of incorporation) (Commission File Number |
|
| March 19, 2024 |
Description of the Company’s Securities EXHIBIT 4.1 DESCRIPTION OF THE COMPANY’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Harrow, Inc. has two classes of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: (i) our common stock, par value $0.001 per share, and (ii) our 8.625% Senior Notes due 2026 (the “2026 Notes”) and 11.875% Senior Notes due 2027 (the “2 |
|
| March 19, 2024 |
Harrow Corporate Presentation dated March 2024 Exhibit 99.3 |
|
| March 19, 2024 |
EXHIBIT 10.46 EXECUTION VERSION THIRD AMENDMENT TO LICENSE AND SUPPLY AGREEMENT This Third Amendment (the “Third Amendment”) is made and entered into as of the th day of January, 2024 (the “Third Amendment Effective Date”) by and between Sintetica S.A., a Swiss corporation having its principal place of business at Via Penate 5, 6850 Mendrisio, Switzerland, (“Sintetica”), and HARROW, INC. (Formerly |
|
| March 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35814 HARROW, INC. ( |
|
| March 19, 2024 |
EXHIBIT 21.1 HARROW, INC. SUBSIDIARIES as of December 31, 2023 Name of Subsidiary State of Incorporation or Organization ImprimisRx, LLC Delaware Imprimis NJOF, LLC New Jersey ImprimisRx NJ, LLC New Jersey Harrow Eye, LLC Delaware Harrow IP, LLC Delaware ImprimisRx Nashville, LLC Delaware Harrow Analytical Services, LLC Delaware |
|
| March 19, 2024 |
Harrow, Inc. Policy Regarding the Mandatory Recovery of Compensation. EXHIBIT 97 HARROW HEALTH, INC. Policy Regarding the Mandatory Recovery of Compensation Effective September 7, 2023 I. Applicability. This Policy Regarding the Mandatory Recovery of Compensation (this “Policy”) applies to any Incentive Compensation paid to Executive Officers of Harrow Health, Inc. (the “Company”). This Policy is intended to comply with and be interpreted in accordance with the requ |
|
| March 19, 2024 |
Letter to Stockholders March 19, 2024 Exhibit 99.2 Letter to Stockholders March 19, 2024 Dear Harrow Stockholders: Please review our new corporate presentation to supplement this Letter to Stockholders. Four Years of Accomplishment The legendary investor Warren Buffett once said, “Some people like to get rich quick, but I like to get rich slow.” Buffett often quoted his friend and former Goldman Sachs senior executive, Gustave “Gus” L |
|
| March 19, 2024 |
Harrow Announces Fourth Quarter and Year-End 2023 Financial Results Exhibit 99.1 Harrow Announces Fourth Quarter and Year-End 2023 Financial Results Full-Year 2023 Highlights: ● Revenues of $130.2 million, an increase of 47% over 2022 revenues of $88.6 million. ● GAAP net loss of $(24.4 million) compared with $(14.1 million) for the prior-year period. ● Adjusted EBITDA of $28.1 million, an increase of 116% over 2022 Adjusted EBITDA of $13.0 million. ● Cash from op |
|
| March 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 19, 2024 HARROW, INC. (Exact name of registrant as specified in its charter) Delaware 001-35814 45-0567010 (State or other jurisdiction of incorporation) (Commission File Number |
|
| February 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 15, 2024 HARROW, INC. (Exact name of registrant as specified in its charter) Delaware 001-35814 45-0567010 (State or other jurisdiction of incorporation) (Commission File Num |
|
| February 15, 2024 |
Harrow Licenses Canadian Rights to Apotex For Five Branded Ophthalmic Pharmaceutical Products Exhibit 99 Harrow Licenses Canadian Rights to Apotex For Five Branded Ophthalmic Pharmaceutical Products NASHVILLE, Tenn. |
|
| February 13, 2024 |
HROW / Harrow, Inc. / Kaufman Daniel Louis - AMENDMENT NO. 1 TO SC13G Passive Investment SC 13G/A 1 sc13g-a1.htm AMENDMENT NO. 1 TO SC13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Harrow, Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 415858109 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to de |
|
| February 13, 2024 |
HROW / Harrow, Inc. / VANGUARD GROUP INC - SCHEDULE 13G Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 Name of issuer: Harrow Inc Title of Class of Securities: Common Stock CUSIP Number: 415858109 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rule pursuant to which this Schedule is filed: ☒ Rule 13d-1(b) ☐ Rule 13d-1(c |
|
| February 9, 2024 |
HROW / Harrow, Inc. / Opaleye Management Inc. Passive Investment SC 13G/A 1 formsc13ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 7 )* HARROW HEALTH, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 415858109 (CUSIP Number) James Silverman, One Boston Place, 26th Floor, Boston, MA 02108 (Name, Address and Telephon |
|
| January 29, 2024 |
Harrow Announces New Appointments to its Board of Directors EXHIBIT 99 Harrow Announces New Appointments to its Board of Directors NASHVILLE, Tenn. |
|
| January 29, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 26, 2024 HARROW, INC. (Exact name of registrant as specified in its charter) Delaware 001-35814 45-0567010 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| January 9, 2024 |
HROW / Harrow, Inc. / Private Capital Management, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Harrow, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 415858109 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of This Statement) Check the appropriate box to designate the rule pursuant to which this Schedule is |
|
| January 3, 2024 |
Melt Pharmaceuticals Provides Corporate Update Exhibit 99 Melt Pharmaceuticals Provides Corporate Update NASHVILLE, Tenn. (January 3, 2024) – Melt Pharmaceuticals, Inc. (“Melt”), a clinical-stage pharmaceutical company developing novel approaches for procedural sedation, today provided a corporate update. The Company previously announced that MELT-300 achieved the primary sedation endpoint in its Phase 2 Pivotal Efficacy and Safety Study in su |
|
| January 3, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 28, 2023 HARROW, INC. (Exact name of registrant as specified in its charter) Delaware 001-35814 45-0567010 (State or other jurisdiction of incorporation) (Commission File Num |
|
| November 24, 2023 |
HROW / Harrow Inc / Kaufman Daniel Louis - SCHEDULE 13G Passive Investment SC 13G 1 sc13g.htm SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Harrow, Inc. (Name of Issuer) Common Shares (Title of Class of Securities) 415858109 (CUSIP Number) November 15, 2023 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule p |
|
| November 13, 2023 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2023 HARROW, INC. (Exact name of registrant as specified in its charter) Delaware 001-35814 45-0567010 (State or other jurisdiction of incorporation) (Commission File Num |
|
| November 13, 2023 |
Harrow Announces Third Quarter 2023 Financial Results Exhibit 99.1 Harrow Announces Third Quarter 2023 Financial Results Third Quarter 2023 and Recent Selected Highlights: ● Record revenues of $34.3 million, an increase of 50% over $22.8 million in the prior-year quarter and an increase of 2% over $33.5 million in the sequential quarter. ● GAAP net loss of $(4.4 million). ● Adjusted EBITDA of $9.2 million, an increase of 270% over $2.5 million in the |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35814 Harrow, Inc. (Ex |
|
| November 13, 2023 |
EXHIBIT 10.2 SECOND AMENDMENT TO LICENSE AND SUPPLY AGREEMENT This Second Amendment (the “Second Amendment”) is made and entered into as of the 4th day of August, 2023 (the “Second Amendment Effective Date”) by and between Sintetica S.A., a Swiss corporation having its principal place of business at Via Penate 5, 6850 Mendrisio, Switzerland, (“Sintetica”), and Harrow IP LLC, a Delaware limited lia |
|
| November 13, 2023 |
Exhibit 99.2 Letter to Stockholders November 13, 2023 Dear Harrow Stockholders: I am pleased to report that Harrow produced record revenues during the third quarter of 2023 of $34.3 million, a 50% increase over quarterly revenues for the prior-year period. Buoyed by demand for IHEEZO®, which is tracking ahead of internal forecasts since its May launch, revenues from Harrow’s branded products were |
|
| November 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2023 HARROW, INC. (Exact name of registrant as specified in its charter) Delaware 001-35814 45-0567010 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| September 29, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 29, 2023 HARROW, INC. (Exact name of registrant as specified in its charter) Delaware 001-35814 45-0567010 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| September 29, 2023 |
Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF HARROW, INC. dated as of September 29, 2023 Table of Contents Page ARTICLE 1 Offices 1 Section 1.1 Registered Office 1 Section 1.2 Other Offices 1 ARTICLE 2 Stockholders’ Meetings 1 Section 2.1 Place of Meetings 1 Section 2.2 Annual Meetings 2 Section 2.3 Special Meetings 2 Section 2.4 Notice of Meetings 2 Section 2.5 Quorum and Voting 4 Section 2.6 Votin |
|
| September 29, 2023 |
Harrow Health, Inc. Changes Corporate Name to Harrow, Inc. Exhibit 99.1 Harrow Health, Inc. Changes Corporate Name to Harrow, Inc. NASHVILLE, Tenn., September 29, 2023 – Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, announced that effective today, it has changed its corporate name from “Harrow Health, Inc.” to “Harrow, Inc.” to align with the Company’s current five-year strategic plan, which includes an exclusive focus on eyecare p |
|
| September 29, 2023 |
Exhibit 3.1 |
|
| August 18, 2023 |
HROW / Harrow Health Inc / BAUM MARK L Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) Under the Securities Exchange Act of 1934 (AMENDMENT NO. 2) HARROW HEALTH, INC. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 415858109 (CUS |
|
| August 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35814 Harrow Health, Inc. ( |
|
| August 9, 2023 |
EXHIBIT 99.2 Letter to Stockholders August 9, 2023 Dear Harrow Stockholders: I am pleased to report second quarter 2023 record revenues of $33.5 million and record adjusted EBITDA of $11.0 million. Notably, we also reported the largest sequential quarterly increase in revenues and adjusted EBITDA in Harrow’s history – from the first to second quarters of 2023. Recall that in my May 11, 2023, Stock |
|
| August 9, 2023 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2023 HARROW HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-35814 45-0567010 (State or other jurisdiction of incorporation) (Commission File |
|
| August 9, 2023 |
Harrow Announces Second Quarter 2023 Financial Results EXHIBIT 99.1 Harrow Announces Second Quarter 2023 Financial Results Second Quarter 2023 and Recent Selected Highlights: ● Record revenues of $33.5 million, an increase of 44% over $23.3 million in the prior-year quarter and an increase of 28% over $26.1 million in the sequential quarter. ● GAAP net loss of ($4.2) million. ● Record adjusted EBITDA of $11.0 million, an increase of 144% over $4.5 mil |
|
| August 9, 2023 |
EXHIBIT 10.1 Execution Version FIRST AMENDMENT TO CREDIT AGREEMENT AND GUARANTY AND CONSENT This FIRST AMENDMENT TO CREDIT AGREEMENT AND GUARANTY AND CONSENT (this “Amendment”), dated as of July 18, 2023 (the “First Amendment Effective Date”), is entered into by and among HARROW HEALTH, INC., a Delaware corporation, (the “Borrower”), the Guarantors (as defined in the Credit Agreement referred to b |
|
| July 21, 2023 |
Exhibit 1.1 Execution Copy HARROW HEALTH, INC. COMMON STOCK, PAR VALUE $0.001 PER SHARE UNDERWRITING AGREEMENT July 18, 2023 B. Riley Securities, Inc. As representative of the several underwriters c/o B. Riley Securities, Inc. 299 Park Avenue, 21st Floor New York, NY 10171 Ladies and Gentlemen: Harrow Health, Inc., a Delaware corporation (the “Company”), proposes to issue and sell to the several U |
|
| July 21, 2023 |
Harrow Prices $60 Million Public Offering of Common Stock Exhibit 99.1 Harrow Prices $60 Million Public Offering of Common Stock NASHVILLE, Tenn., July 19, 2023 – Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced that it priced an underwritten registered public offering of 3,380,282 shares of its common stock at a price of $17.75 per share for aggregate gross proceeds of $60 million. The offering is expected to close o |
|
| July 21, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 18, 2023 HARROW HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-35814 45-0567010 (State or other jurisdiction of incorporation) (Commission File |
|
| July 19, 2023 |
3,380,282 Shares Harrow Health, Inc. Common Stock As Filed Pursuant to Rule 424(b)(5) Registration Statement No. 333-265244 PROSPECTUS SUPPLEMENT (To prospectus dated June 6, 2022) 3,380,282 Shares Harrow Health, Inc. Common Stock We are selling 3,380,282 shares of our common stock, par value $0.001 per share, pursuant to this prospectus supplement and the accompanying prospectus. Our common stock is traded on the Nasdaq Global Market (“Nasdaq”) |
|
| July 18, 2023 |
Exhibit 99.4 Harrow Acquires U.S. and Canadian Commercial Rights to VEVYE® (Cyclosporine Ophthalmic Solution) 0.1% from Novaliq VEVYE® is the First and Only Cyclosporine-Based Product Indicated for the Treatment of Both Signs and Symptoms of Dry Eye Disease with Efficacy Demonstrated After Four Weeks VEVYE® is the Only Water-Free Ophthalmic Product with Convenient Twice-Daily (BID) Dosing NASHVILL |
|
| July 18, 2023 |
Subject to Completion Preliminary Prospectus Supplement dated July 18, 2023 As Filed Pursuant to Rule 424(b)(5) Registration Statement No. 333-265244 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities and we are not soliciting an offer to buy these securities in any state where the offer or sale is not permitted. Subje |
|
| July 18, 2023 |
Harrow Provides Select Preliminary Second Quarter 2023 Financial Guidance Exhibit 99.1 Harrow Provides Select Preliminary Second Quarter 2023 Financial Guidance NASHVILLE, Tenn., July 18, 2023 – Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced the following select preliminary second quarter 2023 financial guidance: ● Second quarter 2023 revenues in excess of $31.0 million compared with prior-year second quarter revenues of $23.3 mill |
|
| July 18, 2023 |
Exhibit 99.5 Harrow Acquires Santen’s Branded Ophthalmic Portfolio Transaction Includes U.S. and Canadian Commercial Rights to FLAREX®, NATACYN®, TOBRADEX® ST, VERKAZIA®, ZERVIATE®, and Non-Prescription Brands FRESHKOTE® and Cationorm® PLUS NASHVILLE, Tenn., July 18, 2023 – Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced the signing of agreements with affiliat |
|
| July 18, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 18, 2023 HARROW HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-35814 45-0567010 (State or other jurisdiction of incorporation) (Commission File |
|
| July 18, 2023 |
Harrow Announces Proposed Public Offering of Common Stock Exhibit 99.2 Harrow Announces Proposed Public Offering of Common Stock NASHVILLE, Tenn., July 18, 2023 – Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced a proposed underwritten registered public offering of its common stock, subject to market and certain other conditions. Harrow expects to grant the underwriters a 30-day option to purchase additional shares of |
|
| July 18, 2023 |
Harrow Health Corporate Presentation dated July 2023 Exhibit 99.3 |
|
| June 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 21, 2023 HARROW HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-35814 45-0567010 (State or other jurisdiction of incorporation) (Commission File |
|
| May 11, 2023 |
Exhibit 99.2 Letter to Stockholders May 11, 2023 Dear Harrow Stockholders: I am pleased to report that the Harrow team delivered record revenues of $26.1 million for the first quarter of 2023. Even more important than this strong sequential topline growth is that we have now entered a new revenue paradigm for Harrow from which we expect revenue growth from our branded pharmaceutical products (“BPP |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2023 HARROW HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-35814 45-0567010 (State or other jurisdiction of incorporation) (Commission File N |
|
| May 11, 2023 |
EXHIBIT 10.2 Execution Copy CREDIT AGREEMENT AND GUARANTY dated as of March 27, 2023 by and among HARROW HEALTH, INC., as the Borrower, THE SUBSIDIARY GUARANTORS FROM TIME TO TIME PARTY HERETO, as the Guarantors, THE LENDERS FROM TIME TO TIME PARTY HERETO, as the Lenders, and OAKTREE FUND ADMINISTRATION, LLC, as the Administrative Agent U.S. $100,000,000 TABLE OF CONTENTS Page Section 1. DEFINITIO |
|
| May 11, 2023 |
EXHIBIT 10.1 Execution Version LOAN AND SECURITY AGREEMENT THIS LOAN AND SECURITY AGREEMENT (as the same may be amended, restated, supplemented, or otherwise modified from time to time, this “Agreement”) dated as of December 14, 2022 (the “Effective Date”) among HARROW HEALTH, INC., a Delaware corporation (“Parent”), HARROW EYE, LLC, a Delaware limited liability company (“Harrow Eye”), HARROW IP, |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35814 Harrow Health, Inc. |
|
| May 11, 2023 |
Harrow Health Corporate Presentation dated May 2023 Exhibit 99.3 |
|
| May 11, 2023 |
Harrow Announces First Quarter 2023 Financial Results Exhibit 99.1 Harrow Announces First Quarter 2023 Financial Results First Quarter 2023 and Recent Selected Highlights: ● Record revenues of $26.1 million, up 18% over $22.1 million for the prior-year quarter and 28% over sequential quarter revenues of $20.3 million. ● Completed transfer of New Drug Applications (NDAs) for ILEVRO®, NEVANAC®, and MAXIDEX®. ● Signed an agreement with a large health in |
|
| April 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definitive |
|
| April 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definitive |
|
| March 28, 2023 |
Harrow Announces New $100 Million Secured Credit Facility with Oaktree Exhibit 99.1 Harrow Announces New $100 Million Secured Credit Facility with Oaktree NASHVILLE, Tenn., March 28, 2023 – Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced that it has entered into a $100 million secured credit financing agreement with funds managed by Oaktree Capital Management, L.P. (“Oaktree”). The interest-only secured credit facility carries an |
|
| March 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2023 HARROW HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-35814 45-0567010 (State or other jurisdiction of incorporation) (Commission File |
|
| March 23, 2023 |
Exhibit 21.1 HARROW HEALTH, INC. SUBSIDIARIES as of December 31, 2022 Name of Subsidiary State of Incorporation or Organization ImprimisRx, LLC Delaware Imprimis NJOF, LLC New Jersey ImprimisRx NJ, LLC New Jersey Harrow Eye, LLC Delaware Harrow IP, LLC Delaware Visionology Equity, LLC Delaware Stowe Pharmaceuticals, Inc. Delaware Radley Pharmaceuticals, Inc. Delaware Mayfield Pharmaceuticals, Inc. |
|
| March 23, 2023 |
Harrow Announces Fourth Quarter and Year-End 2022 Financial Results EXHIBIT 99.1 Harrow Announces Fourth Quarter and Year-End 2022 Financial Results 2022 and Recent Highlights: ● Full-year 2022 revenues of $88.6 million, up 22% over full-year 2021 revenues of $72.5 million ● Sold all non-ophthalmology assets, making Harrow a pure-play ophthalmic pharmaceutical company ● FDA approval of IHEEZO™ topical ocular anesthetic ● CMS issuance of Permanent J-Code (J2403) an |
|
| March 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35814 HARROW HEALTH, |
|
| March 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 23, 2023 HARROW HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-35814 45-0567010 (State or other jurisdiction of incorporation) (Commission File |
|
| March 23, 2023 |
Description of the Company’s Securities Exhibit 4.1 DESCRIPTION OF THE COMPANY’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Harrow Health, Inc. has two classes of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: (i) our common stock, par value $0.001 per share, and (ii) our 8.625% Senior Notes due 2026 (the “2026 Notes”) and 11.875% Senior Notes due 2027 |
|
| March 23, 2023 |
EXHIBIT 99.2 Letter to Stockholders March 23, 2023 Dear Harrow Stockholders: Let me begin with some highlights regarding your Harrow stockholdings. ● This year, we are expecting record revenues and profits, in part, due to: ○ the recent issuance of a permanent J-Code for IHEEZO™ (announced February 2, 2023) and now the authorization of temporary pass-through reimbursement status (announced March 1 |
|
| January 23, 2023 |
Completion of Acquisition or Disposition of Assets, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 20, 2023 HARROW HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-35814 45-0567010 (State or other jurisdiction of incorporation) (Commission Fi |
|
| January 23, 2023 |
EXHIBIT 99.1 Harrow Closes Acquisition of U.S. Rights to ILEVRO®, NEVANAC®, VIGAMOX®, MAXIDEX®, and TRIESENCE® and Will Begin Receiving Net Profit Payments for Acquired Products NASHVILLE, Tenn., January 23, 2023 – Harrow (Nasdaq: HROW), a leading U.S. eyecare pharmaceutical company, today announced the closing of its previously announced acquisition of the exclusive U.S. commercial rights to five |
|
| January 23, 2023 |
UNAUDITED PRO FORMA CONDENSED CONSOLIDATED BALANCE SHEET EXHIBIT 99.2 UNAUDITED PRO FORMA CONDENSED CONSOLIDATED BALANCE SHEET The accompanying unaudited pro forma condensed consolidated balance sheet for Harrow Health, Inc. and subsidiaries (the “Company”) as of September 30, 2022 gives effect to the following transactions: (i) the cash received by the Company in connection with the Company’s sale and divestment of its non-ophthalmology related compoun |
|
| January 20, 2023 |
HROW / Harrow Health Inc / Opaleye Management Inc. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 6 )* HARROW HEALTH, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 415858109 (CUSIP Number) James Silverman, One Boston Place, 26th Floor, Boston, MA 02108 (Name, Address and Telephone Number of Person Authori |
|
| January 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 11, 2023 HARROW HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-35814 45-0567010 (State or other jurisdiction of incorporation) (Commission Fi |
|
| December 20, 2022 |
Exhibit 4.2 Harrow Health, Inc. and U.S. Bank Trust Company, National Association, as Trustee SECOND SUPPLEMENTAL INDENTURE Dated as of December 20, 2022 to the Indenture dated as of April 20, 2021 11.875% Senior Notes due 2027 Table of Contents Page ARTICLE 1 APPLICATION OF SECOND SUPPLEMENTAL INDENTURE 1 Section 1.01. Application of Second Supplemental Indenture. 1 ARTICLE 2 DEFINITIONS 2 Sectio |
|
| December 20, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 14, 2022 HARROW HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-35814 45-0567010 (State or other jurisdiction of incorporation) (Commission F |
|
| December 20, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 HARROW HEALTH, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 45-0567010 (State of Incorporation) (I.R.S. Employer Identification No.) 102 Woodmont Blvd., Suite 610 Nashvill |
|
| December 19, 2022 |
$35,000,000 Harrow Health, Inc. 11.875% Senior Notes due 2027 As Filed Pursuant to Rule 424(b)(5) Registration Statement No. 333-265244 PROSPECTUS SUPPLEMENT (To prospectus dated June 6, 2022) $35,000,000 Harrow Health, Inc. 11.875% Senior Notes due 2027 We are offering $35,000,000 principal amount of our 11.875% senior notes due 2027 (the “Notes”) as described in this prospectus supplement and the accompanying prospectus. Interest on the Notes will accrue f |
|
| December 16, 2022 |
UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL INFORMATION Exhibit 99.2 UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL INFORMATION The accompany unaudited pro forma condensed consolidated balance sheet for Harrow Health, Inc. and subsidiaries (the ?Company?) as of September 30, 2022 gives effect to the following transactions: (i) the cash received by the Company in connection with the Company?s sale and divestment of its non-ophthalmology related co |
|
| December 16, 2022 |
Exhibit 1.1 HARROW HEALTH, INC. COMMON STOCK, PAR VALUE $0.001 PER SHARE UNDERWRITING AGREEMENT December 13, 2022 B. Riley Securities, Inc. As representative of the several underwriters c/o B. Riley Securities, Inc. 299 Park Avenue, 21st Floor New York, NY 10171 Ladies and Gentlemen: Harrow Health, Inc., a Delaware corporation (the ?Company?), proposes to issue and sell to the several Underwriters |
|
| December 16, 2022 |
Exhibit 99.1 Harrow Secures Capital to Close Recently Announced Acquisition Announces Pricing of $35 Million Aggregate Principal Amount Offering of 11.875% Senior Notes Due 2027 NASHVILLE, Tenn., December 16, 2022 ? Harrow Health, Inc. (Nasdaq: HROW), an eyecare pharmaceutical company exclusively focused on the discovery, development, and commercialization of innovative ophthalmic prescription the |
|
| December 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 13, 2022 HARROW HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-35814 45-0567010 (State or other jurisdiction of incorporation) (Commission F |
|
| December 16, 2022 |
Exhibit 1.2 EXECUTION COPY HARROW HEALTH, INC. 11.875% SENIOR NOTES DUE 2027 UNDERWRITING AGREEMENT December 15, 2022 B. Riley Securities, Inc. As representative of the several underwriters c/o B. Riley Securities, Inc. 299 Park Avenue, 21st Floor New York, NY 10171 Ladies and Gentlemen: Harrow Health, Inc., a Delaware corporation (the ?Company?), proposes to issue and sell to the several Underwri |
|
| December 16, 2022 |
HARROW HEALTH, INC. US $35,000,000 11.875% Senior Notes Due 2027 Final Term Sheet December 15, 2022 Filed pursuant to Rule 433 Registration No. 333- 265244 Issuer Free Writing Prospectus Supplementing the Preliminary Prospectus Supplement dated December 14, 2022 HARROW HEALTH, INC. US $35,000,000 11.875% Senior Notes Due 2027 Final Term Sheet December 15, 2022 This pricing term sheet is qualified in its entirety by reference to the Preliminary Prospectus Supplement, dated December 14, 2022 (the |
|
| December 14, 2022 |
Harrow Prices $25 Million Offering Exhibit 99.2 Harrow Prices $25 Million Offering NASHVILLE, Tenn., December 14, 2022 – Harrow Health, Inc. (Nasdaq: HROW), an eyecare pharmaceutical company exclusively focused on the discovery, development, and commercialization of innovative ophthalmic prescription therapies, today announced that it priced an underwritten registered offering of 2,376,426 shares of its common stock at a price of $ |
|
| December 14, 2022 |
EXHIBIT 99.1 Harrow Enters into Agreement to Acquire Exclusive U.S. Rights to ILEVRO®, NEVANAC®, VIGAMOX®, MAXIDEX®, and TRIESENCE® NASHVILLE, Tenn., December 14, 2022 – Harrow (Nasdaq: HROW), an eyecare pharmaceutical company exclusively focused on the discovery, development, and commercialization of innovative ophthalmic therapies, today announced that it has entered into a binding agreement for |
|
| December 14, 2022 |
Road Show Materials, dated December 2022 Exhibit 99.3 |
|
| December 14, 2022 |
2,376,426 Shares Harrow Health, Inc. Common Stock As Filed Pursuant to Rule 424(b)(5) Registration Statement No. 333-265244 PROSPECTUS SUPPLEMENT (To prospectus dated June 6, 2022) 2,376,426 Shares Harrow Health, Inc. Common Stock We are selling 2,376,426 shares of our common stock, par value $0.001 per share, pursuant to this prospectus supplement and the accompanying prospectus. Our common stock is traded on the Nasdaq Global Market (?Nasdaq?) |
|
| December 14, 2022 |
Subject to Completion Preliminary Prospectus Supplement dated December 14, 2022 As Filed Pursuant to Rule 424(b)(5) Registration Statement No. 333-265244 The information in this preliminary prospectus supplement and the accompanying prospectus is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities, and they are not soliciting an offer to buy these securities in any jurisdiction where |
|
| December 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 13, 2022 HARROW HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-35814 45-0567010 (State or other jurisdiction of incorporation) (Commission F |
|
| December 14, 2022 |
EX-99.1 2 ex99-1.htm EXHIBIT 99.1 Harrow Announces Proposed Offering of $100 Million of Senior Notes Due 2027 and “BB” Rating from Egan-Jones NASHVILLE, Tenn., December 14, 2022 – Harrow Health, Inc. (Nasdaq: HROW), an eyecare pharmaceutical company exclusively focused on the discovery, development, and commercialization of innovative ophthalmic prescription therapies, today announced that it has |
|
| December 14, 2022 |
EXHIBIT 10.1 ASSET PURCHASE AGREEMENT by and among NOVARTIS TECHNOLOGY LLC and NOVARTIS INNOVATIVE THERAPIES AG and HARROW HEALTH, INC., HARROW EYE, LLC and HARROW IP, LLC DATED AS OF December 13, 2022 TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS 2 1.1 Definitions 2 1.2 Other Capitalized Terms 10 1.3 Interpretive Provisions 11 ARTICLE 2 SALE AND TRANSFER OF ASSETS 12 2.1 Purchase and Sale of Trans |
|
| December 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 14, 2022 HARROW HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-35814 45-0567010 (State or other jurisdiction of incorporation) (Commission F |
|
| November 14, 2022 |
EXHIBIT 10.1 FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS FIRST AMENDMENT TO LOAN AND SECURITY AGREEMENT (this ?Amendment?) dated as of April 8, 2022 (the ?Amendment Effective Date?), is made among HARROW HEALTH, INC., a Delaware corporation (?Lender?), MELT PHARMACEUTICALS, INC., a Delaware corporation (?Borrower?), and certain subsidiaries of the Borrower from time to time party to the Lo |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35814 Harrow Health, I |
|
| November 14, 2022 |
EXHIBIT 10.2 SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT THIS SECOND AMENDMENT TO LOAN AND SECURITY AGREEMENT (this ?Amendment?) dated as of September 21, 2022 (the ?Amendment Effective Date?), is made among HARROW HEALTH, INC., a Delaware corporation (?Lender?), MELT PHARMACEUTICALS, INC., a Delaware corporation (?Borrower?), and certain subsidiaries of the Borrower from time to time party to |
|
| November 14, 2022 |
Harrow Announces Third Quarter 2022 Financial Results Exhibit 99.1 Harrow Announces Third Quarter 2022 Financial Results Selected Recent Highlights: ? FDA approval of IHEEZO? for ocular surface anesthesia ? Launch of Fortisite?, fortified antibiotics ? Launch of atropine.com? compounded atropine portal ? Revenues of $22.8 million, up 22% over $18.7 million for the prior-year quarter ? Nearly $1 million firm order revenue backlog at September 30, 2022 |
|
| November 14, 2022 |
EXHIBIT 99.2 Letter to Stockholders November 14, 2022 Dear Harrow Stockholders: I am pleased to report third quarter results that included 22% year-over-year revenue growth and the company remaining ?in the black? while we prepare to launch IHEEZO?, generate new high-value revenues from our portfolio of FDA-approved branded pharmaceutical products (BPPs), and advance our market-leading ImprimisRx |
|
| November 14, 2022 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2022 HARROW HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-35814 45-0567010 (State or other jurisdiction of incorporation) (Commission F |
|
| November 14, 2022 |
EXHIBIT 10.3 October 7, 2022 VIA EMAIL Imprimis Rx, LLC 12264 El Camino Real Suite 350 San Diego, California 92130 Attn: John Saharek Email: [email protected] Re: Commercial Alliance Agreement: Mutual Termination Dear John: EyePoint Pharmaceuticals, Inc. (?EyePoint?) and ImprimisRx, LLC (?Imprimis?) entered into a Commercial Alliance Agreement effective as of August 1, 2020, as modified by t |
|
| October 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 7, 2022 HARROW HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-35814 45-0567010 (State or other jurisdiction of incorporation) (Commission Fil |
|
| October 5, 2022 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 30, 2022 HARROW HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-35814 45-0567010 (State or other jurisdiction of incorporation) (Commission |
|
| October 5, 2022 |
Harrow Sells Non-Ophthalmic Compounding Business Exhibit 99.1 Harrow Sells Non-Ophthalmic Compounding Business NASHVILLE, Tenn., October 5, 2022 ? Harrow (Nasdaq: HROW), an eyecare pharmaceutical company exclusively focused on the discovery, development, and commercialization of innovative ophthalmic therapies, today announced the sale of its non-ophthalmic compounding business to Innovation Compounding Pharmacy, LLC, an affiliate of Revelation |
|
| September 22, 2022 |
Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 21, 2022 HARROW HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-35814 45-0567010 (State or other jurisdiction of incorporation) (Commission |
|
| August 9, 2022 |
EXHIBIT 99.2 Letter to Stockholders August 9, 2022 Dear Harrow Stockholders: Today I was delighted to report our eighth consecutive quarter of record financial results, including the addition of nearly $5 million in new cash generated from operations, making the cash position on our balance sheet at the end of the second quarter a total of more than $46 million. Our business remains strong, and as |
|
| August 9, 2022 |
Exhibit 10.1 LOAN AND SECURITY AGREEMENT THIS LOAN AND SECURITY AGREEMENT (?Agreement?), dated as of the 1st day of September, 2021 (the ?Closing Date?), is made and entered into on the terms and conditions hereinafter set forth, by and among MELT PHARMACEUTICALS, INC., a Delaware corporation (?Borrower?); certain subsidiaries of Borrower from time to time party hereto as guarantors (each a ?Guara |
|
| August 9, 2022 |
Harrow Health, Inc. Corporate Presentation dated August 2022 Exhibit 99.3 |
|
| August 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 or ?? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35814 Harrow Health, Inc. |
|
| August 9, 2022 |
EXHIBIT 99.1 Harrow Health Announces Second Quarter 2022 Financial Results Revenues Increase for Eighth Consecutive Quarter Highlights for Second Quarter 2022: ? Record revenues of $23.3 million, up 29% over $18.1 million for the prior-year quarter ? Record gross profit of $16.8 million, up 22% over $13.7 million for the prior-year quarter ? A record 718,000 product units shipped, up 4% from the p |
|
| August 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2022 HARROW HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-35814 45-0567010 (State or other jurisdiction of incorporation) (Commission File |
|
| June 13, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2022 HARROW HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-35814 45-0567010 (State or other jurisdiction of incorporation) (Commission File N |
|
| June 1, 2022 |
June 1, 2022 Via EDGAR Submission Securities and Exchange Commission 100 F Street, N. |
|
| May 26, 2022 |
EX-FILING FEES 5 ex107.htm CALCULATION OF FILING FEE TABLES Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) HARROW HEALTH, INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Security Maximum |
|
| May 26, 2022 |
Amendment to Amended and Restated Certificate of Incorporation, filed July 10, 2018. Exhibit 3.2 CERTIFICATE OF AMENDMENT OF AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF IMPRIMIS PHARMACEUTICALS, INC. The corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware does hereby certify: FIRST: That at a meeting of the Board of Directors of Imprimis Pharmaceuticals, Inc. resolutions were duly adopted setting forth a proposed |
|
| May 26, 2022 |
As filed with the Securities and Exchange Commission on May 26, 2022 As filed with the Securities and Exchange Commission on May 26, 2022 Registration No. |
|
| May 5, 2022 |
Harrow Health, Inc. Letter to Stockholders EXHIBIT 99.2 Harrow Health, Inc. Letter to Stockholders May 5, 2022 To the Stockholders of Harrow Health, Inc.: It’s a great honor to let you know that the Harrow team has delivered another consecutive quarter of record financial results, including a 43% increase in year-over-year revenues and a nearly 10% increase in sequential-quarter revenues. Business remains good and the future for Harrow rem |
|
| May 5, 2022 |
EXHIBIT 99.1 Harrow Health Announces First Quarter 2022 Financial Results Seventh Consecutive Quarter of Record Results Highlights for First Quarter 2022: ● Record revenues of $22.1 million, up 43% over $15.4 million for the prior-year quarter ● Record gross profit of $16.2 million, up 38% over $11.7 million for the prior-year quarter ● Record number of 689,000 product units shipped, up 72% from t |
|
| May 5, 2022 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2022 HARROW HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-35814 45-0567010 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| May 5, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35814 Harrow Health, Inc. |
|
| April 26, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive |
|
| April 26, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy State |
|
| April 13, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 8, 2022 HARROW HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-35814 45-0567010 (State or other jurisdiction of incorporation) (Commission File |
|
| March 31, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 31, 2022 HARROW HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-35814 45-0567010 (State or other jurisdiction of incorporation) (Commission File |
|
| March 10, 2022 |
Exhibit 10.50 Portions of this exhibit indicated by bracketed asterisks have been omitted because they are not material and would likely cause competitive harm to Harrow Health, Inc. if publicly disclosed. December 6, 2021 VIA EMAIL Imprimis Rx, LLC 12264 El Camino Real Suite 350 San Diego, California 92130 Attn: John Saharek Email: Re: Commercial Alliance Agreement: Expansion of Imprimis Responsi |
|
| March 10, 2022 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2022 HARROW HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-35814 45-0567010 (State or other jurisdiction of incorporation) (Commission File |
|
| March 10, 2022 |
Exhibit 10.51 ASSET PURCHASE AGREEMENT by and between NOVARTIS TECHNOLOGY LLC and NOVARTIS OPHTHALMICS AG and HARROW HEALTH, INC. DATED AS OF 17 DECEMBER, 2021 TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS 1 1.1 Definitions 1 1.2 Other Capitalized Terms 9 1.3 Interpretive Provisions 9 ARTICLE 2 SALE AND TRANSFER OF ASSETS 10 2.1 Purchase and Sale of Transferred Assets. 10 2.2 No Transfer of Certain |
|
| March 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35814 HARROW HEALTH, |
|
| March 10, 2022 |
Exhibit 21.1 HARROW HEALTH, INC. SUBSIDIARIES as of December 31, 2021 Name of Subsidiary State of Incorporation or Organization ImprimisRx, LLC Delaware Imprimis NJOF, LLC New Jersey ImprimisRx NJ, LLC New Jersey Imprimis Pharmaceuticals USA, LLC Delaware Harrow IP, LLC Delaware Visionology Equity, LLC Delaware Stowe Pharmaceuticals, Inc. Delaware Radley Pharmaceuticals, Inc. Delaware Mayfield Pha |
|
| March 10, 2022 |
Harrow Health, Inc. Letter to Stockholders EXHIBIT 99.2 Harrow Health, Inc. Letter to Stockholders March 10, 2022 To the Stockholders of Harrow Health, Inc.: As a result of the remarkable collective effort of the Harrow family of employees and the patronage of our valued customers, it is my privilege to report that the fourth quarter of 2021 was our sixth consecutive quarter of record performance in many key financial and operational metri |
|
| March 10, 2022 |
EXHIBIT 99.1 Harrow Health Announces Fourth Quarter and Year-End 2021 Financial Results Sixth Consecutive Quarter of Record Revenues Highlights for Fourth Quarter 2021: ? Record revenues of $20.2 million, a 38% increase compared with $14.6 million for the prior-year quarter; ? Gross profit was a record $15.1 million, a 42% increase compared with $10.7 million for the prior-year quarter; ? Gross ma |
|
| March 10, 2022 |
Description of the Company’s Securities Exhibit 4.1 DESCRIPTION OF THE COMPANY?S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Harrow Health, Inc. has two classes of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended: (i) our common stock, par value $0.001 per share, and (ii) our 8.625% Senior Notes due 2026 (the ?Senior Notes? or ?Notes?). In this exhibit, whe |
|
| January 28, 2022 |
ETON / Eton Pharmaceutcials, Inc. / Imprimis Pharmaceuticals, Inc. Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A (AMENDMENT NO. 1) (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO ? 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO ? 240.13d-2(a) Under the Securities Exchange Act of 1934 Eton Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 29772L 108 (CUSIP Nu |
|
| January 26, 2022 |
HROW / Harrow Health Inc / Opaleye Management Inc. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* HARROW HEALTH, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 415858109 (CUSIP Number) James Silverman, One Boston Place, 26th Floor, Boston, MA 02108 (Name, Address and Telephone Number of Person Authoriz |
|
| January 10, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 10, 2022 HARROW HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-35814 45-0567010 (State or other jurisdiction of incorporation) (Commission Fi |
|
| January 10, 2022 |
Harrow Health, Inc. Tear Sheet dated January 2022 Exhibit 99.2 |
|
| January 10, 2022 |
Exhibit 99.1 . |
|
| December 20, 2021 |
Exhibit 99.1 Harrow Health Acquires U.S. Commercial Rights to Four Branded Eye Drops Expands and Strengthens Portfolio of Product Offerings for U.S. Ophthalmic Surgical and Acute Care Markets NASHVILLE, Tenn., December 20, 2021 ? Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic-focused healthcare company, today announced its acquisition of the exclusive U.S. commercialization rights of four FDA-a |
|
| December 20, 2021 |
Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 17, 2021 HARROW HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-35814 45-0567010 (State or other jurisdiction of incorporation) (Commission F |
|
| December 9, 2021 |
Exhibit 99.1 EyePoint Pharmaceuticals and Harrow Health?s ImprimisRx Announce Expanded U.S. Commercial Alliance for DEXYCU? ? ImprimisRx to assume full responsibility for U.S. sales and marketing activities for DEXYCU? and absorb the majority of EyePoint?s DEXYCU commercial organization; EyePoint to retain DEXYCU NDA, revenue recognition, manufacturing and distribution responsibilities for all mar |
|
| December 9, 2021 |
Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 6, 2021 HARROW HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-35814 45-0567010 (State or other jurisdiction of incorporation) (Commission Fi |
|
| November 9, 2021 |
Harrow Health, Inc. Letter to Stockholders Exhibit 99.2 Harrow Health, Inc. Letter to Stockholders November 9, 2021 To the Stockholders of Harrow Health, Inc.: I am pleased to provide our stockholders with the good news that our team has delivered strong top-line revenue and year-over-year earnings growth and, in many other key operational metrics, a fifth consecutive quarter of company records. I hope our stockholders like the phrase, ?gr |
|
| November 9, 2021 |
EXHIBIT 10.4 Portions of this exhibit indicated by bracketed asterisks have been omitted because they are not material and would likely cause competitive harm to Harrow Health, Inc. if publicly disclosed. LICENSE AGREEMENT BY AND BETWEEN WAKAMOTO PHARMACEUTICAL CO., LTD. AND HARROW HEALTH, INC. AUGUST 18, 2021 1 LICENSE AGREEMENT This License Agreement (this ?Agreement?) is made effective as of th |
|
| November 9, 2021 |
Exhibit 99.1 Harrow Health Announces Third Quarter 2021 Financial Results Revenues Reach Record Levels for Fifth Consecutive Quarter Highlights for Third Quarter 2021: ? Record revenues of $18.7 million, a 30% increase compared with $14.4 million for the prior-year period; ? Gross margin of 74% consistent with prior-year period; ? Acquired AMP-100 late-stage ophthalmic surgical drug candidate for |
|
| November 9, 2021 |
Exhibit 10.3 Portions of this exhibit indicated by bracketed asterisks have been omitted because they are not material and would likely cause competitive harm to Harrow Health, Inc. and Wakamoto Pharmaceutical Co., LTD. if publicly disclosed. BASIC SALE AND PURCHASE AGREEMENT This BASIC SALE AND PURCHASE AGREEMENT (hereinafter referred to as this ?Agreement?) made and entered into this 18th day of |
|
| November 9, 2021 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2021 HARROW HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-35814 45-0567010 (State or other jurisdiction of incorporation) (Commission Fi |
|
| November 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 5, 2021 HARROW HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-35814 45-0567010 (State or other jurisdiction of incorporation) (Commission Fi |
|
| November 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35814 Harrow Health, I |
|
| September 10, 2021 |
102 Woodmont Blvd. Suite 610 Nashville, TN 37205 Main: 615.733.4330 www.harrowinc.com September 10, 2021 Via EDGAR Submission Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Attention: Michael Davis Re: Harrow Health, Inc. Registration Statement on Form S-3 (SEC File No. 333-259326), originally filed on September 3, 2021 Ladies and Gentlemen: In connection with the Reg |
|
| September 3, 2021 |
As filed with the Securities and Exchange Commission on September 3, 2021 As filed with the Securities and Exchange Commission on September 3, 2021 Registration No. |
|
| September 2, 2021 |
Exhibit 10.1 Execution Version LOAN AND SECURITY AGREEMENT THIS LOAN AND SECURITY AGREEMENT (?Agreement?), dated as of the 1st day of September, 2021 (the ?Closing Date?), is made and entered into on the terms and conditions hereinafter set forth, by and among MELT PHARMACEUTICALS, INC., a Delaware corporation (?Borrower?); certain subsidiaries of Borrower from time to time party hereto as guarant |
|
| September 2, 2021 |
Exhibit 99.1 Harrow Health Provides $13.5 Million Senior Secured Loan to Melt Pharmaceuticals Melt Expects to Dose First Patient in MELT-300 Phase 2 Study During September 2021 NASHVILLE, Tenn., (September 2, 2021) ? Harrow Health, Inc. (Nasdaq: HROW), an ophthalmic-focused healthcare company, and Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company developing first-in-class medicin |
|
| September 2, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 1, 2021 HARROW HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-35814 45-0567010 (State or other jurisdiction of incorporation) (Commission F |
|
| August 23, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 19, 2021 HARROW HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-35814 45-0567010 (State or other jurisdiction of incorporation) (Commission Fil |
|
| August 18, 2021 |
Harrow Health Acquires Ophthalmic Surgical Drug Candidate from Wakamoto Pharmaceutical Co., Ltd. EXHIBIT 99.1 Harrow Health Acquires Ophthalmic Surgical Drug Candidate from Wakamoto Pharmaceutical Co., Ltd. NASHVILLE, Tenn. and TOKYO, August 18, 2021 ? Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic-focused healthcare company, today announced that it has entered into an agreement with Wakamoto Pharmaceutical Co., Ltd. to acquire the U.S. and Canadian commercial rights for drug candidate MAQ |
|
| August 18, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 18, 2021 HARROW HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-35814 45-0567010 (State or other jurisdiction of incorporation) (Commission Fil |
|
| August 10, 2021 |
EXHIBIT 10.2 Portions of this exhibit indicated by bracketed asterisks have been omitted because they are not material and would likely cause competitive harm to Harrow Health, Inc. if publicly disclosed. LICENSE AND SUPPLY AGREEMENT This License and Supply Agreement (this ?Agreement?) is made effective as of the last date of signature below (the ?Effective Date?) by and between Sintetica S.A., a |
|
| August 10, 2021 |
Harrow Health, Inc. Letter to Stockholders EXHIBIT 99.2 Harrow Health, Inc. Letter to Stockholders August 10, 2021 To the Stockholders of Harrow Health, Inc.: Harrow continues to be a reliable and innovative pharmaceutical supplier to hundreds of thousands of Americans and many thousands of eyecare institutions across the country, including optometrists, ophthalmologists, ambulatory surgery centers, and hospitals. As a result of our commit |
|
| August 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 or ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35814 Harrow Health, Inc. ( |
|
| August 10, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2021 HARROW HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-35814 45-0567010 (State or other jurisdiction of incorporation) (Commission Fil |
|
| August 10, 2021 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2021 HARROW HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-35814 45-0567010 (State or other jurisdiction of incorporation) (Commission Fil |
|
| August 10, 2021 |
EXHIBIT 99.1 Harrow Health Announces Second Quarter 2021 Financial Results Fourth Consecutive Quarter of Record Results Highlights for Second Quarter 2021:7 ? Record revenues of $18.1 million, a 125% increase compared with $8.1 million for the prior-year period; ? Gross margin was 75.6%, compared with 60.2% for the prior-year period; ? GAAP operating income increased to $4.2 million compared with |
|
| August 10, 2021 |
Harrow Health, Inc. Corporate Presentation dated August 2021 |
|
| July 27, 2021 |
Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 25, 2021 HARROW HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-35814 45-0567010 (State or other jurisdiction of incorporation) (Commission File |
|
| July 27, 2021 |
EX-99.1 2 ex99-1.htm Exhibit 99.1 Harrow Health Acquires Patented Ophthalmic Surgical Drug Candidate from Sintetica New Drug Application Expected to Be Filed in Late 2021 NASHVILLE, Tenn. and MENDRISIO, Switzerland, July 27, 2021 – Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic-focused healthcare company, today announced that it has entered into an agreement with Sintetica, S.A., a growing phar |
|
| July 21, 2021 |
Other Events, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 21, 2021 HARROW HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-35814 45-0567010 (State or other jurisdiction of incorporation) (Commission File |
|
| July 21, 2021 |
Exhibit 99.1 Surface Ophthalmics Announces $25 Million Private Round of Fundraising Proceeds from the capital raise will help to support and advance Surface?s ongoing clinical programs in ocular diseases PLEASANTON, California, 21 July 2021 ? Surface Ophthalmics, Inc., a pharmaceutical company focused on the development and commercialization of innovative therapeutics for ocular diseases, today an |
|
| June 25, 2021 |
As filed with the Securities and Exchange Commission on June 25, 2021 As filed with the Securities and Exchange Commission on June 25, 2021 Registration No. |
|
| June 17, 2021 |
Exhibit 99.2 Harrow Health Announces Closing of $20 Million Aggregate Principal Amount Offering of 8.625% Senior Notes Due 2026 NASHVILLE, Tenn., June 17, 2021 ? Harrow Health, Inc. (NASDAQ: HROW) (?Harrow Health? or the ?Company?), an ophthalmic-focused healthcare company, today announced the closing of its underwritten registered public offering of $20 million aggregate principal amount of 8.625 |
|
| June 17, 2021 |
EXHIBIT 99.1 Harrow Health Announces Pricing of $17.5 Million Aggregate Principal Amount Offering of 8.625% Senior Notes Due 2026 NASHVILLE, Tenn., June 14, 2021 ? Harrow Health, Inc. (NASDAQ: HROW) (?Harrow Health? or the ?Company?), an ophthalmic-focused healthcare company, today announced the pricing of its underwritten registered public offering of $17.5 million aggregate principal amount of 8 |
|
| June 17, 2021 |
Exhibit 1.1 EXECUTION COPY HARROW HEALTH, INC. 8.625% SENIOR NOTES DUE 2026 UNDERWRITING AGREEMENT June 14, 2021 B. Riley Securities, Inc. As representative of the several underwriters c/o B. Riley Securities, Inc. 299 Park Avenue, 21st Floor New York, NY 10171 Ladies and Gentlemen: Harrow Health, Inc., a Delaware corporation (the ?Company?), proposes to issue and sell to the several Underwriters |
|
| June 17, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 17, 2021 (June 14, 2021) HARROW HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-35814 45-0567010 (State or other jurisdiction of incorporation) ( |
|
| June 15, 2021 |
Harrow Health, Inc. 8.625% Senior Notes due 2026 As Filed Pursuant to Rule 424(b)(5) Registration Statement No. 333-239669 PROSPECTUS SUPPLEMENT (To prospectus dated July 13, 2020) $17,500,000 Harrow Health, Inc. 8.625% Senior Notes due 2026 We are offering $17,500,000 principal amount of our 8.625% senior notes due 2026 (the ?Notes?) as described in this prospectus supplement and the accompanying prospectus. Interest on the Notes will accrue fr |
|
| June 14, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 14, 2021 HARROW HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-35814 45-0567010 (State or other jurisdiction of incorporation) (Commission File |
|
| June 14, 2021 |
Exhibit 99.1 Harrow Health Announces Offering of $17.5 Million of 8.625% Senior Notes Due 2026 and ?BB? Rating from Egan-Jones NASHVILLE, Tenn., June 14, 2021 ? Harrow Health, Inc. (NASDAQ: HROW) (?Harrow Health? or the ?Company?), an ophthalmic-focused healthcare company, today announced that it has commenced an underwritten registered public offering of $17.5 million aggregate principal amount o |
|
| June 14, 2021 |
HARROW HEALTH, INC. US $18,025,000 8.625% Senior Notes Due 2026 Final Term Sheet June 14, 2021 Filed pursuant to Rule 433 Registration No. 333- 239669 Issuer Free Writing Prospectus Supplementing the Preliminary Prospectus Supplement dated June 14, 2021 HARROW HEALTH, INC. US $18,025,000 8.625% Senior Notes Due 2026 Final Term Sheet June 14, 2021 This pricing term sheet is qualified in its entirety by reference to the Preliminary Prospectus Supplement, dated June 14, 2021 (the ?Preliminary |
|
| June 14, 2021 |
Subject to Completion Preliminary Prospectus Supplement dated JUNE 14, 2021 As Filed Pursuant to Rule 424(b)(5) Registration Statement No. 333-239669 The information in this preliminary prospectus supplement and the accompanying prospectus is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities, and they are not soliciting an offer to buy these securities in any jurisdiction where |
|
| June 7, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 3, 2021 HARROW HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-35814 45-0567010 (State or other jurisdiction of incorporation) (Commission File N |
|
| May 19, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) [ ] Definitive P |
|
| May 11, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-35814 Harrow Health, Inc. (Ex |
|
| May 11, 2021 |
Harrow Health Announces Record First Quarter 2021 Financial Results Exhibit 99.1 Harrow Health Announces Record First Quarter 2021 Financial Results Highlights for First Quarter 2021: ? Revenues of $15.4 million, a 31% increase compared with $11.8 million for prior year; ? Adjusted EBITDA(1), a non-GAAP measure, reached a new high of $4.3 million, compared with $0.4 million for prior year; ? Segment contribution from ImprimisRx increased to $5.7 million for the fi |
|
| May 11, 2021 |
Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2021 HARROW HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-35814 45-0567010 (State or other jurisdiction of incorporation) (Commission File N |
|
| May 11, 2021 |
Harrow Health, Inc. Letter to Stockholders Exhibit 99.2 Harrow Health, Inc. Letter to Stockholders May 11, 2021 To the Stockholders of Harrow Health, Inc.: The first quarter of 2021 was our best financial quarter in company history. Before I try to back-up the above statement with some data, it?s worth taking a moment to revisit my last Letter to Stockholders, particularly the first page, to provide context for this and future Letters to S |
|
| May 5, 2021 |
EXHIBIT 3.1 CERTIFICATE OF DESIGNATION OF SERIES B CUMULATIVE PREFERRED STOCK OF HARROW HEALTH, INC. Pursuant to the General Corporation Law of the State of Delaware Harrow Health, Inc., a Delaware corporation (the ?Corporation?), hereby certifies, that pursuant to the authority expressly vested in the Board of Directors of the Corporation (the ?Board?) by the Amended and Restated Certificate of I |
|
| May 5, 2021 |
Harrow Health Raises Approximately $11 Million in Sale of Series B Preferred Stock EXHIBIT 99.1 Harrow Health Raises Approximately $11 Million in Sale of Series B Preferred Stock NASHVILLE, Tenn., May 5, 2021 ? Harrow Health, Inc. (NASDAQ: HROW) (?Harrow Health? or the ?Company?), an ophthalmic-focused healthcare company, today announced that the Company has closed on a private sale to B. Riley Securities, Inc. of 440,000 shares of its newly created Series B Cumulative Preferred |
|
| May 5, 2021 |
Harrow Health Announces Full Exercise and Closing of Option to Purchase Additional Senior Notes EXHIBIT 99.2 Harrow Health Announces Full Exercise and Closing of Option to Purchase Additional Senior Notes NASHVILLE, Tenn., May 5, 2021 ? Harrow Health, Inc. (NASDAQ: HROW) (?Harrow Health? or the ?Company?), an ophthalmic-focused healthcare company, today announced the closing of an additional $5.0 million of 8.625% senior notes due 2026 (the ?Additional Notes?), pursuant to the exercise in fu |
|
| May 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 5, 2021 (April 30, 2021) HARROW HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-35814 45-0567010 (State or other jurisdiction of incorporation) (C |
|
| May 5, 2021 |
UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL INFORMATION Exhibit 99.3 UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL INFORMATION The table below sets forth the unaudited pro forma condensed consolidated balance sheet for Harrow Health, Inc. (the ?Company?) as of December 31, 2020 giving effect to: (i) the sale of a portion of the Company?s investment in the common stock of Eton Pharmaceuticals, Inc., net of costs, which sale closed on April 12, 20 |
|
| May 5, 2021 |
Execution Version EXHIBIT 10.1 Securities Purchase Agreement This Securities Purchase Agreement (the ?Agreement?) dated as of May 5, 2021 (the ?Effective Date?) between: (a) Harrow Health, Inc., a Delaware corporation (the ?Company?) and (b) B. Riley Securities, Inc. (together with any participating affiliates, the ?Purchaser?). The Company and the Purchaser are individually, a ?Party? and are col |
|
| April 27, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (AMENDMENT NO. 1) (Rule 13d-101) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2(a) Under the Securities Exchange Act of 1934 HARROW HEALTH, INC. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 4 |
|
| April 23, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) [X] |
|
| April 23, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant [X] Filed by a Party other than the Registrant [ ] Check the appropriate box: [ ] Preliminary Proxy Statement [ ] Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) [ ] Definitive P |
|
| April 20, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 20, 2021 (April 15, 2021) HARROW HEALTH, INC. (Exact name of registrant as specified in its charter) Delaware 001-35814 45-0567010 (State or other jurisdiction of incorporation) |
|
| April 20, 2021 |
Exhibit 4.1 HARROW HEALTH, INC. TO U.S. BANK NATIONAL ASSOCIATION AS TRUSTEE INDENTURE DATED AS OF APRIL 20, 2021 SENIOR DEBT SECURITIES TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS AND OTHER PROVISIONS OF GENERAL APPLICATION 1 Section 1.1 Definitions 1 Section 1.2 Compliance Certificates and Opinions 7 Section 1.3 Form of Documents Delivered to Trustee 7 Section 1.4 Section 1.4 Acts of Holders; R |
|
| April 20, 2021 |
Harrow Health Announces Pricing of $50 Million Offering of Senior Notes Due 2026 Exhibit 99.1 Harrow Health Announces Pricing of $50 Million Offering of Senior Notes Due 2026 NASHVILLE, Tenn., April 15, 2021 – Harrow Health, Inc. (NASDAQ: HROW) (“Harrow Health” or the “Company”), an ophthalmic-focused healthcare company, today announced the pricing of its underwritten registered public offering of $50 million aggregate principal amount of 8.625% senior notes due 2026 (the “Not |
|
| April 20, 2021 |
U.S. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 HARROW HEALTH, INC. (Exact Name of Registrant as Specified in Its Charter) Delaware 45-0567010 (State of Incorporation or Organization) (I.R.S. Employer Identification No.) 102 Woodmont Blvd., Suite 610 N |
